References in periodicals archive ?
DB160 is a lead dipeptidylpeptidase (DPPIV) inhibitor from a family of DPPIV inhibitors.
This article focuses on recent developments in the management of type 2 diabetes; specifically, the legacy effect and macrovascular disease, glycaemic targets and macrovascular disease, glycaemic management (specifically focusing on initiation of insulin therapy and the group of agents shortly to be introduced in South Africa, the incretins and DPPIV inhibitors) and the role of self-monitoring of blood glucose (SMBG).
Incretin mimetics and DPPIV inhibitors in the treatment of type 2 diabetes mellitus.
He also discussed the advantages and disadvantages of DPPIV Inhibitor groups.
Acronyms browser ?
Full browser ?